Search and analyze individual stocks with comprehensive metrics
Vivo Bio Tech
Fundamental Score
Vivo Bio Tech Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of VIVOBIOT across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (39.39%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 9.16 vs Industry: 64.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (688.24%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (23.49%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Limited Growth History (-3.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (4.25% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Weak Interest Coverage (2.42x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-28.72 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Biotechnology sector...
Financial Statements
Comprehensive financial data for Vivo Bio Tech
About VIVOBIOT
Company Details
Market Information
Performance
VIVOBIOT Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of VIVOBIOT?
VIVOBIOT is currently trading at ₹37.52 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of VIVOBIOT shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of VIVOBIOT and what does it mean?
VIVOBIOT has a P/E ratio of 9.16x compared to the industry average of 64.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹9 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is VIVOBIOT performing according to Bull Run's analysis?
VIVOBIOT has a Bull Run fundamental score of 37.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 11.01%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does VIVOBIOT belong to?
VIVOBIOT operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Vivo Bio Tech. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for VIVOBIOT?
VIVOBIOT has an ROE of 11.01%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Vivo Bio Tech generates profits from shareholders' equity. An ROE of 11% means the company generates ₹11 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is VIVOBIOT's debt-to-equity ratio and what does it indicate?
VIVOBIOT has a debt-to-equity ratio of 0.69, which indicates moderate leverage that should be monitored. This means the company has ₹69 of debt for every ₹100 of equity. Higher leverage can amplify returns during good times but increases bankruptcy risk during downturns.
What is VIVOBIOT's dividend yield and is it a good dividend stock?
VIVOBIOT offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has VIVOBIOT grown over the past 5 years?
VIVOBIOT has achieved 5-year growth rates of: Sales Growth -3.35%, Profit Growth 10.40%, and EPS Growth 4.25%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in VIVOBIOT and why does it matter?
Promoters hold 36.43% of VIVOBIOT shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: -6.93%.
How does VIVOBIOT compare with its industry peers?
VIVOBIOT trades at P/E 9.16x vs industry average 64.77x, with ROE of 11.01% and ROCE of 12.56%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether VIVOBIOT is outperforming its competitive set in profitability, growth, and valuation metrics.
What is VIVOBIOT's market capitalization and what category does it fall into?
VIVOBIOT has a market capitalization of ₹77 crores, making it a Mid-cap stock. Mid-cap stocks balance growth potential with moderate risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for VIVOBIOT?
Key ratios for VIVOBIOT: ROE 11.01% (Good), ROCE 12.56%, P/E 9.16x, Debt-to-Equity 0.69, Interest Coverage 2.42x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is VIVOBIOT stock and what is its beta?
VIVOBIOT has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for VIVOBIOT?
VIVOBIOT has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹37.52, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in VIVOBIOT?
Key risks for VIVOBIOT include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.69), and operational challenges. The stock has a Fundamental Score of 37.7/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is VIVOBIOT's operating profit margin and how has it trended?
VIVOBIOT has a 5-year average Operating Profit Margin (OPM) of 39.39%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is VIVOBIOT's quarterly performance in terms of sales and profit growth?
VIVOBIOT's recent quarterly performance shows YoY Sales Growth of 23.49% and YoY Profit Growth of 688.24%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in VIVOBIOT?
VIVOBIOT has FII holding of 0.00% and DII holding of 0.00%, totaling 0.00% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.